Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-03-04 | Reverse | 1:9 |
| 2025-07-03 | Reverse | 1:21 |
| 2023-09-28 | Reverse | 1:26 |
SciSparc Ltd. is a Tel Aviv-based clinical-stage pharma company developing cannabinoid-based drugs for conditions like Tourette’s, sleep apnea, Alzheimer’s, pain, autism, and epilepsy, with multiple clinical trials and partnerships.

The MUSE™ system is a single-use endoscopic device for minimally invasive transoral fundoplication to treat GERD, marking SciSparc’s entry into the $billion medical device market with commercialization planned after acquiring its IP in January 2026.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
INDP | $1.14 | COMPARE |
JSPR | $0.70 | COMPARE |
ARTL | $0.66 | COMPARE |
ONCO | $0.61 | COMPARE |
PTIX | $0.98 | COMPARE |
SLXN | $0.36 | COMPARE |
LIPO | $0.00 | COMPARE |
SCNI | $2.51 | COMPARE |